Correlation Between Parathormon and Sexual Hormones in Patients on Haemodialysis
Vahidin Sahovic, Sanela Sahovic, Emir Grosa, Emir Avdic, Dzana Helac-Cvijetic, Nihad Kukavica
Med Arh. 2012; 66(3): 177-180
Introduction: Chronic renal failure is associated with endocrine abnormalities, which in some cases cause polyendocrinopathy responsible for the symptoms and complications. The consequence of secondary hyperparathyroidism is not only bone disease but may be cardiovascular disorders, peripheral nerve damage and impact on the level of sex hormones. The aim of this study was to evaluate the interactions between parathyroid hormone and sexual hormones and the effect of elevated levels of parathyroid hormone secretion on various sexual hormones. The study included 72 patients who were undergoing chronic hemodialysis program 3 times a week at the Clinic for hemodialysis. Patients were divided into two groups according to parathyroid hormone values and child-bearing age. The study is a retrospective-prospective and lasted for 1 year. At the beginning, after 6 months, and at the end of the study were determined the PTH, FSH, LH, progesterone, testosterone, β-estradiol, prolactin. Results: During the study period followed are the values of sexual hormones and PTH in 72 patients of which 41 men and 31 women. Of these 33.3% (24) men were in the reproductive age, and 23.6% (17) were women in the reproductive age. The mean age of patients was 53.2±12.16, and the average duration of hemodialysis was 7.57±4.0. PTH showed a slight tendency to increase 274.45±220.74 pg/dL at baseline, at the end of study 383±313.2 also increased during the study was recorded and the values progesterone. Statistically significant effect of PTH showed the FSH p<0.01LH p<0.05 and prolactin p<0.01. On average, patients who have elevated PTH levels have lower values of FSH and LH, but higher prolactin values. Parathormone also shows the effect on β estradiol at level p<0.01, patients with higher PTH values have lower levels of β estradiol. Conclusion: The increase in the number of younger people with terminal renal insufficiency treated by repeated hemodialysis, often have endocrine disorders and elevated PTH. Normalization of PTH levels affects the normalization of sexual hormone levels and improves quality of life of patients on hemodialysis.
1. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
2. Block eet al. Hyperphosphatemia J Am Soc nephrol 2004;15:2008-18
3. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate level and mortality risk among people with chronic kidney disease J Am Soc Nephrol 2005;16:520-526.
4. Go As, Chentow GM, Fan D, McCullock CE, HSU CY. Chronic kidney disease and risk of death. Cardiovascular events and hospitalization. N Eng J Med 2004;351:1296-305
5. Roland I, Robert EM, Genevieve C, Raymond JP, Raymond A. Effect of parathyroid hormone on plasma prolactin inh man Clin Endo and metab 1978;47:18-23.
6. Bogićević M, Kostić S, Stefanović V. Koncentracija prolaktina u serumu bolesnika lečenih ponovljenim hemodijalizama i posle presađivanja bubrega Acta Facultatis medicae Naissensis 1989;9:33-9
7. Fioretti P, Melid GB, Ciardella F, Barsotti G, Orlandi MC, Paoletti AM, Giovanetti S. Parathyroid function and pituatarygonadal axis in male uremics;effects of dietary treatment and of maintance haemodilysis. 1986;25:155-158.
8. Massry SG, Goldstein DA, Procci WR, Kletzky OA. Impotence in patients with uremia: a posible role for parathyroid hormone. Nephron 1977;19:305-310
9. Greenberg C, Kukreja SC, Bowser EN, Hargis GK, Henderson WJ, Wiliams GA. Parathyroid hormone secretion: Effect on estradiol and progesterone. Metabolism 1987;36:151-154
10. Moe Sm, Drueke TB. Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003;23:369-379
11. Clinical practice guidelines for the management of bone metabolism disorders in CKD patients: Am J Kidney Dis 2004;42(Supl 3):S 1-S202.
12. Backerman BS, Silver J. Vitamin D and parathyroid. Am J Med Sci 1999;6:363-369.
13. Marx SJ. Medical Progress: Hyperparathyroid and hypoparathyroid disorders. Rev N Engl J Med 2000;343:1863-75
14. Isaac R, Merceron RE, Caillens G, Raymond JP, Ardaillou P. Effect of parathyroid hormone on plasma prolactin in man. J Clin Endocrin Metabol 1978;47:18-21
15. Isaac R, Merceron RE, Caillens G, Raymond J.P. Ardaillon R. Effect of parathyroid hormone on plasma prolactin in men J Clin Endocrinol Metab 1978;47:18-23.
16. Mooradin AD, Morley SE: Endocrine dysfunction in chronic renal failure Arch Intem Med 1984;144:351-353
17. Abram HS, Hester LR, Sheridan WF, Epstein GM:Sexualy functioning in patients with chronic renal failure J. Nerv. Ment. Dis 160:220-226 (1975)
18. Maastrogiacomo I, De Besi L, Serafimi E, Zussa S, Zuchetta P, Romagnoli CF, Saporili E, Dean P, Ronco C, Adami A. Hyperprolactinemia and sexual disturbances among uremic women on hemodialysis Nephron 1984;37:195-199.
19. Franks S, Jacobs HS. Hyperprolactinemia. Clin Endocrin Metab 1983;12:641-668
20. Slatopolsky E, Dusso A, Brown AJ. The role of phosphorus in the development of secondary hyperparathyroidism and paranoid cell proliferation in chronic renal failure Am J Med Sci 1996;6:370-376.